Literature DB >> 29589547

Implication of B23/NPM1 in Viral Infections, Potential Uses of B23/NPM1 Inhibitors as Antiviral Therapy.

Yadira Lobaina1, Yasser Perera2.   

Abstract

BACKGROUND: B23/nucleophosmin (B23/NPM1) is an abundant multifunctional protein mainly located in the nucleolus but constantly shuttling between the nucleus and cytosol. As a consequence of its constitutive expression, intracellular dynamics and binding capacities, B23/NPM1 interacts with multiple cellular factors in different cellular compartments, but also with viral proteins from both DNA and RNA viruses. B23/NPM1 influences overall viral replication of viruses like HIV, HBV, HCV, HDV and HPV by playing functional roles in different stages of viral replication including nuclear import, viral genome transcription and assembly, as well as final particle formation. Of note, some virus modify the subcellular localization, stability and/or increases B23/NPM1 expression levels on target cells, probably to foster B23/NPM1 functions in their own replicative cycle.
RESULTS: This review summarizes current knowledge concerning the interaction of B23/NPM1 with several viral proteins during relevant human infections. The opportunities and challenges of targeting this well-conserved host protein as a potentially new broad antiviral treatment are discussed in detail. Importantly, although initially conceived to treat cancer, a handful of B23/NPM1 inhibitors are currently available to test on viral infection models.
CONCLUSION: As B23/NPM1 partakes in key steps of viral replication and some viral infections remain as unsolved medical needs, an appealing idea may be the expedite evaluation of B23/NPM1 inhibitors in viral infections. Furthermore, worth to be addressed is if the up-regulation of B23/NPM1 protein levels that follows persistent viral infections may be instrumental to the malignant transformation induced by virus like HBV and HCV. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  B23/NPM1; antiviral drug; antiviral therapy; inhibitors; nucleophosmin; viral infections; virus.

Mesh:

Substances:

Year:  2019        PMID: 29589547     DOI: 10.2174/1871526518666180327124412

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  6 in total

Review 1.  New targets for HIV drug discovery.

Authors:  Ana C Puhl; Alfredo Garzino Demo; Vadim A Makarov; Sean Ekins
Journal:  Drug Discov Today       Date:  2019-03-15       Impact factor: 7.851

Review 2.  Nucleophosmin in Its Interaction with Ligands.

Authors:  Ilaria Cela; Adele Di Matteo; Luca Federici
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

3.  Identification of potentially anti-COVID-19 active drugs using the connectivity MAP.

Authors:  Raphaël Bonnet; Lee Mariault; Jean-François Peyron
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

4.  Targeting CK2 mediated signaling to impair/tackle SARS-CoV-2 infection: a computational biology approach.

Authors:  Jamilet Miranda; Ricardo Bringas; Jorge Fernandez-de-Cossio; Yasser Perera-Negrin
Journal:  Mol Med       Date:  2021-12-20       Impact factor: 6.354

Review 5.  The nucleolus, an ally, and an enemy of cancer cells.

Authors:  Dariusz Stępiński
Journal:  Histochem Cell Biol       Date:  2018-08-13       Impact factor: 4.304

6.  Targeting of Protein Kinase CK2 Elicits Antiviral Activity on Bovine Coronavirus Infection.

Authors:  Ailyn C Ramón; George V Pérez; Evelin Caballero; Mauro Rosales; Daylén Aguilar; Dania Vázquez-Blomquist; Yassel Ramos; Arielis Rodríguez-Ulloa; Viviana Falcón; María Pilar Rodríguez-Moltó; Ke Yang; Yasser Perera; Silvio E Perea
Journal:  Viruses       Date:  2022-03-07       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.